Litigation Details for Salix Pharmaceuticals, Ltd. v. Norwich Pharmaceuticals, Inc. (D. Del. 2020)
✉ Email this page to a colleague
Salix Pharmaceuticals, Ltd. v. Norwich Pharmaceuticals, Inc. (D. Del. 2020)
Docket | ⤷ Sign Up | Date Filed | 2020-03-26 |
Court | District Court, D. Delaware | Date Terminated | 2022-08-10 |
Cause | 35:271 Patent Infringement | Assigned To | Richard Gibson Andrews |
Jury Demand | None | Referred To | |
Parties | ALVOGEN PB RESEARCH AND DEVELOPMENT LLC | ||
Patents | 10,314,828; 10,335,397; 10,456,384; 6,861,053; 7,045,620; 7,417,042; 7,612,199; 7,737,112; 7,902,206; 7,906,542; 7,915,275; 7,928,115; 8,158,644; 8,158,781; 8,193,196; 8,207,125; 8,309,569; 8,518,949; 8,642,573; 8,741,904; 8,829,017; 8,835,452; 8,853,231; 8,946,252; 8,969,398; 9,271,968; 9,421,195; 9,623,001; 9,629,828 | ||
Attorneys | Ricardo S. Camposanto | ||
Firms | JPMorgan Chase & Co. | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in Salix Pharmaceuticals, Ltd. v. Norwich Pharmaceuticals, Inc.
Biologic Drugs cited in Salix Pharmaceuticals, Ltd. v. Norwich Pharmaceuticals, Inc.
Details for Salix Pharmaceuticals, Ltd. v. Norwich Pharmaceuticals, Inc. (D. Del. 2020)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
0000-00-00 | External link to document | |||
2020-03-26 | 1 | Complaint | (the “’9,828 patent”); 10,314,828 (the “’4,828 patent”); 10,335,397 (the “’397 patent”); and 10,456,…; 8,969,398; 9,271,968; 9,421,195; 9,629,828; 10,314,828; 10,335,397; and 10,456,384 by submitting ANDA…; 8,969,398; 9,271,968; 9,421,195; 9,629,828; 10,314,828; 10,335,397; and 10,456,384 under 35 U.S.C. … 8,969,398; 9,271,968; 9,421,195; 9,629,828; 10,314,828; 10,335,397; and 10,456,384 remain valid and … 8,969,398; 9,271,968; 9,421,195; 9,629,828; 10,314,828; 10,335,397; and 10,456,384, inclusive of any | External link to document |
2021-08-03 | 118 | Notice of Service | the Invalidity of U.S. Patent Nos. 8,642,573; 8,969,398; 9,421,195; 10,335,397; and 10,709,694 4. Opening…Bergstrom, Ph.D. Regarding the Invalidity of U.S. Patent No. 7,906,542 2. Opening Expert of Michael J. Zaworotko…Zaworotko, Ph.D. Regarding the Invalidity of U.S. Patent Nos. 7,045,620; 7,612,199; 7,902,206; and 7,906,542…2020 10 August 2022 1:20-cv-00430 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |